<DOC>
	<DOC>NCT00658359</DOC>
	<brief_summary>This is a study that will follow transplant patients from Study A3921030 to monitor for long term safety, tolerability and efficacy for 5 additional years, except in Portugal where the study will follow transplant patients through Month 36 posttransplant. Patients will continue their study medications that were previously assigned.</brief_summary>
	<brief_title>Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients</brief_title>
	<detailed_description />
	<mesh_term>Tofacitinib</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Subjects who successfully completed Study A3921030 Subjects who are on the waiting list for a second kidney transplant or any nonrenal organ transplants</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Immunosuppression</keyword>
	<keyword>JAK3 inhibitor</keyword>
	<keyword>kidney transplantation</keyword>
</DOC>